Strategic Outsourcing in Clinical Development

Advances in automation technologies and bioprocessing equipment are driving fuller adoption of automation in biomanufacturing.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

The benefits include reduced contamination risks, simplified validation processes, and streamlined operations.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Takeda’s TAKHZYRO (lanadelumab) is now approved in Europe as a subcutaneous injection treatment for hereditary angioedema in patients 12 years old and above and in adults.

RNA modalities will especially benefit from fuller adoption of continuous manufacturing platforms.